PHAR - שווי פעילות Pharming Group N.V.
Commercial solutions from Pharming Group N.V. (PHAR) for combating rare immune pathologies are growing actively, as confirmed by the price action on the GURU.Markets platform, where the metric stands at 808.63. The business relies on the orphan drug segment, leading in the therapy of hereditary angioedema via Ruconest and gene technologies. High authority among physicians and patients in Europe solidifies its status as a reliable supplier of life-saving medications.
Pharming Group N.V. (PHAR) - פילוחי מדדים ודוחות פיננסיים
The enterprise value of Pharming Group N.V. (PHAR) reflects the total cost of acquiring the business within the orphan drug sector. This metric aggregates market capitalization and debt obligations, minus existing cash reserves. By analyzing the market valuation of assets excluding liquidity, an investor sees the real value of all operational resources. Stable demand for rare medicines ensures predictable flows, smoothing the dynamics of this indicator. Such resilience minimizes the risks of a sharp revaluation of the company.